Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases

…, T Ogura, M Otaola, D Skowasch… - European …, 2018 - Eur Respiratory Soc
… have experienced disease progression: a relative decline of ≥10% in forced vital capacity
(FVC); a relative decline of ≥15% in diffusing capacity of the lung for carbon monoxide (D

[HTML][HTML] Swarm learning for decentralized and confidential clinical machine learning

…, S Kim-Hellmuth, J Nattermann, D Skowasch… - Nature, 2021 - nature.com
… Before using the data in machine learning, we performed a rank transformation to normality
on datasets B, D and E. In brief, transcript expression values were transformed from RNA-…

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised …

…, B Sigal, AS Orellana, D Skowasch… - The lancet Respiratory …, 2020 - thelancet.com
Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …

[HTML][HTML] COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension

…, H Kaemmerer, HJ Kabitz, D Skowasch… - European …, 2022 - Eur Respiratory Soc
Background Risk stratification plays an essential role in the management of patients with
pulmonary arterial hypertension (PAH). The current European guidelines propose a three-…

[HTML][HTML] Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients

…, M ToVinh, V Keitel, G Rieke, V Talevi, D Skowasch… - Genome medicine, 2021 - Springer
Background The SARS-CoV-2 pandemic is currently leading to increasing numbers of
COVID-19 patients all over the world. Clinical presentations range from asymptomatic, mild …

[PDF][PDF] Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19

…, J Schulte-Schrepping, D Schunk, D Skowasch… - Immunity, 2020 - cell.com
Temporal resolution of cellular features associated with a severe COVID-19 disease
trajectory is needed for understanding skewed immune responses and defining predictors of …

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry

…, H Wilkens, W Randerath, D Skowasch… - European …, 2015 - Eur Respiratory Soc
After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF)
in 2011, we investigated clinical management practices for patients with IPF according to …

Strategy for safe performance of extrathoracic magnetic resonance imaging at 1.5 tesla in the presence of cardiac pacemakers in non–pacemaker-dependent patients …

…, A Schmiedel, C Meyer, K Strach, D Skowasch… - Circulation, 2006 - Am Heart Assoc
Background— The purpose of the present study was to evaluate a strategy for safe
performance of extrathoracic magnetic resonance imaging (MRI) in non–pacemaker-dependent …

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma …

…, T Schaum, C Schulz, D Skowasch… - The lancet respiratory …, 2021 - thelancet.com
Background ANDHI was done to assess the efficacy of benralizumab, including onset of effect
and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and …

[HTML][HTML] Clinical trials with combination of cytokine-induced killer cells and dendritic cells for cancer therapy

…, MA Gonzalez-Carmona, D Skowasch… - International Journal of …, 2019 - mdpi.com
… The complementary subsequent addition of anti-CD3 acts as a mitogenic stimulus and
high doses of IL-2 principally promote the expression of the natural killer group 2 member D (…